Stockreport

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile

Sangamo Therapeutics, Inc.  (SGMO) 
Last sangamo therapeutics, inc. earnings: 2/28 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.sangamo.com
PDF - Sustained elevated expression of alpha-galactosidase A (a-Gal A) activity maintained for up to three years for the longest-treated patient as of the data cutoff date.- [Read more]